deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03654768

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease

Sponsor: National Cancer Institute (NCI)

Conditions Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions Bosutinib Dasatinib Imatinib Laboratory Biomarker Analysis Nilotinib Ruxolitinib
Updated 17 times since 2018 Last updated: Dec 2, 2025 Started: Oct 24, 2018 Primary completion: Jul 1, 2024 Completion: Jul 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 17 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2018 – ~Jul 2019 · 10 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2020 · 13 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Jan 2023 · 7 months · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Dec 2023 · 7 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

17 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  5. May 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  10. Sep 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  11. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  12. Sep 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Adrian, United States , Albuquerque, United States , Allentown, United States , Alton, United States , American Fork, United States , Ames, United States , Anaconda, United States , Anchorage, United States , Ann Arbor, United States and 300 more locations